This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
by Zacks Equity Research
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
by Zacks Equity Research
AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
by Zacks Equity Research
Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
by Zacks Equity Research
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Intercept Reports Phase III Sub-Study Liver Biopsy Data
by Zacks Equity Research
Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
by Zacks Equity Research
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
by Zacks Equity Research
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Amgen Announces Acceptance of MAA for Evenity in Europe
by Zacks Equity Research
Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.
5 Small-Cap Stocks Set to Explode Higher in 2018
by Sweta Killa
Small caps are poised to surge in 2018 given tax cuts and improving domestic economy.
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?
by Zacks Equity Research
GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
Catabasis' DMD Candidate Slows Disease Progression, Stock Up
by Zacks Equity Research
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
by Zacks Equity Research
Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.
Top Ranked Momentum Stocks to Buy for September 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 11th:
Sarepta's Golodirsen Positive in DMD Study, Shares Soar
by Zacks Equity Research
Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.
Sarepta Appoints Ex-Allergan Executive as CEO and President
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
by Zacks Equity Research
Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.